Viatris (VTRS) Non Operating Interest Expenses (2020 - 2026)
Viatris (VTRS) posted Non Operating Interest Expenses of $120.7 million for Q2 2026, little changed on a QoQ basis from $120.1 million in Q1 2026, and up 3.52% year-over-year from $116.6 million in Q2 2025.
Analysis
Viatris (VTRS) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends
Viatris has reported Non Operating Interest Expenses for 7 years, with the latest figure at $120.7 million in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 3.52% year-over-year to $120.7 million in Q2 2026; TTM through Jun 2026 was $480.0 million, a 3.6% decrease from a year earlier, with the FY2025 full-year figure at $471.3 million, down 14.31% from the prior year.
- Non Operating Interest Expenses was $120.7 million for Q2 2026 at Viatris, roughly flat from $120.1 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $153.2 million in Q3 2022, with the low at $115.5 million in Q1 2025.
- Average Non Operating Interest Expenses over 5 years is $134.9 million, with a median of $141.2 million recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses dropped 20.03% in 2025, then rose 3.98% in 2026.
- Over 5 years, Non Operating Interest Expenses stood at $147.1 million in 2022, then decreased by 4.21% to $140.9 million in 2023, then declined by 14.69% to $120.2 million in 2024, then decreased by 0.5% to $119.6 million in 2025, then grew by 0.92% to $120.7 million in 2026.
- The last three Non Operating Interest Expenses figures came in at $120.7 million (Q2 2026), $120.1 million (Q1 2026), and $119.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.57 Bn | 38.91 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.20 Bn | 18.31 Bn | 1.46 Bn | 120.70 Mn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | -13.26 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.36 Bn | 520.75 Mn | 2.10 Bn | 396.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -41.02 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 995.52 Mn | 705.40 Mn | 93.47 Mn | 6.66 Mn |
| 9 | Fennec Pharmaceuticals | 406.25 Mn | 365.00 Mn | 17.15 Mn | 3,000.00 |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 120.70 Mn |
| Mar 31, 2026 | 120.10 Mn |
| Dec 31, 2025 | 119.60 Mn |
| Sep 30, 2025 | 119.60 Mn |
| Jun 30, 2025 | 116.60 Mn |
| Mar 31, 2025 | 115.50 Mn |
| Dec 31, 2024 | 120.20 Mn |
| Sep 30, 2024 | 145.60 Mn |
| Jun 30, 2024 | 145.80 Mn |
| Mar 31, 2024 | 138.40 Mn |
| Dec 31, 2023 | 140.90 Mn |
| Sep 30, 2023 | 141.50 Mn |
| Jun 30, 2023 | 143.70 Mn |
| Mar 31, 2023 | 147.00 Mn |
| Dec 31, 2022 | 147.10 Mn |
| Sep 30, 2022 | 153.20 Mn |
| Jun 30, 2022 | 145.90 Mn |
| Mar 31, 2022 | 146.20 Mn |
| Dec 31, 2021 | 148.20 Mn |
| Sep 30, 2021 | 151.90 Mn |